KKR Secures $2.1B Loan for Integer Buyout
KKR secured a $2.1B loan for its $5.7B acquisition of Integer, with strong investor demand tightening terms. The loan was priced at 2.5% over benchmark, up to 0.5% tighter than initial discussions. Citigroup led the sale. Bloomberg data shows limited LBO financing this year, driving high demand. KKR aims to complete the Integer buyout by year-end, signaling robust credit market activity.
How this was made
The 30-second read
Why it matters
The financing reduces execution risk for the acquisition, supporting KKR's pipeline and likely lifting both stocks.
Market read
The transaction underscores strong leveraged loan market activity and ongoing consolidation in the healthcare device sector.
What to watch
Possible regulatory scrutiny of medical‑device consolidation and the impact of tighter loan pricing on future deals.
Background
KKR arranged a $2.1B loan to fund its cash purchase of Integer amid heightened demand for LBO financing.
Ticker impact
KKR secured a $2.1B loan to fund its $5.7B cash acquisition of Integer, tightening the interest margin to 2.5% over benchmark.
Potential short‑term upside for KKR as the acquisition moves forward.
Primary disclosure of large‑scale financing confirms deal viability, reducing uncertainty.
Integer agreed to be acquired by KKR for about $5.7B cash, with the $2.1B loan now in place.
Expect ITGR shares to rise as the transaction approaches closing.
Deal terms are disclosed for the first time, providing clear upside catalyst.
Market effects
Reinforces momentum in healthcare device M&A and signals strong appetite for leveraged buyouts.
Adds pressure to US leveraged loan market, potentially tightening credit spreads.
Highlights robust global demand for large‑scale buyout financing.
Counterpoint
The added debt could over‑leverage KKR if credit conditions deteriorate.
Key entities
- CompanyKKR & Co. Inc.
Private equity firm financing the Integer buyout.
- CompanyInteger Holdings Corp.
Medical‑device maker being acquired for $5.7B.
